GSA Capital Partners LLP Buys 37,275 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

GSA Capital Partners LLP raised its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 66.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 93,658 shares of the company's stock after buying an additional 37,275 shares during the quarter. GSA Capital Partners LLP owned about 0.08% of Centessa Pharmaceuticals worth $1,498,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of CNTA. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company's stock worth $40,000 after purchasing an additional 826 shares during the period. GAMMA Investing LLC increased its holdings in Centessa Pharmaceuticals by 103.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company's stock valued at $48,000 after buying an additional 1,509 shares during the period. Quarry LP increased its stake in Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company's stock valued at $87,000 after acquiring an additional 3,108 shares during the period. Sandia Investment Management LP acquired a new position in Centessa Pharmaceuticals during the second quarter worth $90,000. Finally, Fred Alger Management LLC acquired a new stake in shares of Centessa Pharmaceuticals during the second quarter worth approximately $99,000. Institutional investors and hedge funds own 82.01% of the company's stock.

Analyst Upgrades and Downgrades

CNTA has been the topic of a number of recent analyst reports. Guggenheim boosted their price objective on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a "buy" rating in a research note on Wednesday, September 11th. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $11.00 to $26.00 in a report on Thursday, September 19th. B. Riley began coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a "buy" rating and a $33.00 target price on the stock. BMO Capital Markets boosted their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an "outperform" rating in a report on Monday, September 16th. Finally, Oppenheimer reissued an "outperform" rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $25.17.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA traded down $0.51 during trading hours on Thursday, hitting $17.57. The company had a trading volume of 260,413 shares, compared to its average volume of 401,652. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of -11.82 and a beta of 1.47. The company has a quick ratio of 13.29, a current ratio of 13.29 and a debt-to-equity ratio of 0.27. The business has a fifty day moving average of $15.81 and a 200-day moving average of $12.03. Centessa Pharmaceuticals plc has a 12 month low of $5.58 and a 12 month high of $18.74.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.05. Equities analysts anticipate that Centessa Pharmaceuticals plc will post -1.68 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Saurabh Saha sold 4,169 shares of the business's stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total value of $51,362.08. Following the completion of the sale, the chief executive officer now owns 827,755 shares of the company's stock, valued at approximately $10,197,941.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Saurabh Saha sold 4,169 shares of the business's stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total value of $51,362.08. Following the completion of the sale, the chief executive officer now directly owns 827,755 shares in the company, valued at approximately $10,197,941.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Gregory M. Weinhoff sold 25,000 shares of the firm's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $15.00, for a total value of $375,000.00. Following the transaction, the insider now owns 223,369 shares in the company, valued at approximately $3,350,535. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 325,031 shares of company stock valued at $5,213,043. Insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.